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Detection of Lipocortin 1 in Human Lung
Lavage Fluid: Lipocortin Degradation As a
Possible Proteolytic Mechanism in the Control
of Inflammatory Mediators and Inflammation
by Susan F. Smith,* Teresa D. Tetley,* Abraham Guz,* and
Roderick J. Flower'
Lipocortins are structurally related, glucocorticoid-inducible proteins that inhibit phopholipase A2
(PLA2), thereby reducing the liberation of arachidonic acid from phospholipids and so limiting the
synthesis of eicosanoid inflammatory mediators. This study is the first demonstration of one lipocor-
tin, lipocortin 1 (Lc 1; 37 kDa), inhuman lunglavage supernatants. In lavage fluid from healthy volunteers,
a higher percentage (> 70%) ofthe detected Lc 1 was in its native form, compared to that from patients
with abnormal lungs. In patients' lavage fluids, Lc 1 was more likely to be partially degraded (34 kDa).
In abnormal bronchoalveolar lavage fluid (BALF), the more polymorphonuclear neutrophils
(PMN)/lavage, the lower the proportion ofLc 1 in the native (37 kDa) form (n = 7 pairs, rs = - 0.8214,
p < 0.05). Furthermore, whenBALF cells were cultured andthe harvested conditioned media incubated
with pure human recombinant Lc 1, degradation of the 37 kDa form increased with the percentage of
PMN (n = 10 pairs, s = - 0.7200 after 1 hr; n = 6 pairs, rs = - 0.9241 after 6 hr). These results suggest
that factors released from the PMN are responsible for Lc 1 degradation in man. When recombinant
human Lc 1 was incubated with human neutrophil elastase, the enzyme degraded Lc 1 ina dose-dependent
way, suggesting that neutrophil elastase may be one such factor. Since PMNs are ubiquitous at sites
of inflammation, it is possible that Lc 1 degradation is a permissive mechanism, which ensures that
sufficient inflammation occurs to destroy the provocative stimulus. However, it is equally possible that,
in some circumstances, the mechanism may be pathological and that the inactivation of Lc 1 leads to
chronic, uncontrolled inflammation.
Introduction
Although glucocorticoids have been used empirically
in the treatment of inflammatory diseases for 40 years,
their mechanisms of action are only now being eluci-
dated. Studies in animals show that the anti-inflam-
matory actions of steroids can be mediated, at least in
part, by a family of structurally related proteins named
lipocortins 1 through 6. These anti-inflammatory pro-
teins, which are synthesized in response to both naturally
occurring and synthetic glucocorticoids (1,2), inhibit
phospholipase A2 (PLA2). This prevents the release from
phospholipid of arachidonic acid, the common precur-
sor ofboth prostaglandin and leukotriene inflammatory
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mediators. Although lipocortins are produced by human
cells (3,4) and human lipocortin genes have been cloned
(5), the exact role of these proteins in human health and
disease has yet to be understood.
As yet, there are no published data on lipocortin in the
human lung, whether healthy or abnormal, although
lipocortins are present in rat (6) and bovine (7) lungs.
However, there is evidence that human lung cells can
produce steroid-inducible inhibitors of arachidonic acid
release (8), one of which may be a lipocortin.
A previously published study has shown that lipocor-
tin 1 (Lc 1; 37 kDa), the most widely distributed and best
characterized member of the lipocortin family, can be
proteolyzed in vitro by an elastase (probably porcine
pancreatic elastase) (9) to a number of products, with
molecular weights ranging from 18 to 33 kDa. The func-
tional significance of one such fragment (33 kDa) is of
particular interest. Unpublished studies (Flower et al.)
show that in vivo, the 33-kPa form loses the ability to
suppress inflammation; furthermore, it fails to reduce
prostaglandin production and release by peritoneal
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macrophages maintained in vitro, although it appears
to retain 90% of its PLA2 inhibitory capacity in one cell-
free in vitro assay system (9). In addition, when the
37-kDa protein is proteolyzed, as well as the 33-kDa
form, a 3-kDa fragment is liberated from the N-terminal
portion of the parent molecule. There is some evidence
that peptides with sequence homology to this 3-kDa frag-
ment may have some inherent anti-inflammatory activi-
ty. For example, similar peptides are able to block formyl-
methionyl-leucyl-phenylalanine (fmlp)-induced chemo-
taxis in polymorphonuclear neutrophils (PMN) (10),
although these effects occur at high concentrations that
are probably nonphysiological. It therefore seems likely
that proteolysis of Lc 1 could have significant patho-
logical effects.
Elastase activities in the human lung are greatly in-
creased by tobacco smoking (11); in addition, elevated
elastase activities have been implicated in the etiology
ofmany pulmonary diseases including smoking-related
disorders and some environmentally induced diseases
(12), as well as certain congenital diseases (13).
The first aim of the present study was to establish
whether or not Lc 1 is present in the human lung. To do
this, lung lavage fluids from healthyhuman subjects and
from patients with various lung diseases were analyzed
for Lc 1 and for itsbreakdown products. The second aim
of the current investigation was to determine whether
or not Lc 1 was degraded (inactivated?) by purified
human neutrophil elastase (NE) and, if so, to find out
if the actions of NE on lipocortin could be reproduced
by exposure of recombinant Lc 1 to media in which
elastase-secreting cells (PMN, and alveolar macrophages,
AM) had been cultured.
Methods
Materials
Double-lumened, balloon-tipped catheters(5Fand 6F)
were obtained from Kimal Scientific Products Ltd. (Ux-
bridge, Middx., UK). Centricon units were purchased
from Amicon Ltd. (Stonehouse, Glos., UK). The
PhastSystem electrophoresis apparatus and SDS-
polyacrylamide gradient Phastgels to use on it were
obtained from Pharmacia Ltd. (Milton Keynes, Bucks,
UK), while the dot-blotting apparatus and nitrocellulose
paper were purchased from Bio-Rad Laboratories Ltd.
(Hemel Hempstead, Herts., UK). The Chromoscan 3 gel
scanner was from Joyce-Loebl (Gateshead, Tyne and
Wear, UK). All tissue culture media were obtained from
Gibco Ltd. (Paisley, Renfrewshire, UK). Rainbow molecu-
lar weight markers were purchased from Amersham In-
ternational plc (Amersham, Bucks, UK). Goat anti-rabbit
IgG conjugated to horseradish peroxidase was obtained
from Sigma Chemical Co. Ltd. (Poole, Dorset, UK).
Neutrophil elastase and its substrate, insoluble elastin,
were ordered from Elastin Products Ltd. (Pacific, MO).
Recombinant human Lc 1 and monospecific antibodies
to the whole molecule were the gifts of Biogen Inc.
(Cambridge, MA). All other chemicals were of AnalaR
grade and were purchased fromBDH Ltd. (Poole, Dorset,
UK).
Subjects
Peripheral lung lavage fluid (PLF;14) was collected
from 6 volunteers (1 male; 6 smokers; median age 26
years, range 22-31 years)who underwent bronchoscopy
solely for research purposes. Informed consent was ob-
tained from all subjects by a clinician who was not in-
volved in the study, and approval was obtained from the
Local Ethical Committee of Charing Cross Hospital.
In addition, PLF was obtained during routine fibre-
optic bronchoscopy of 11 patients (5 male; 4 nonsmokers,
4 exsmokers, and 3 current smokers; median age 68
yrs, range 56-78 years). The final diagnoses on these pa-
tients were: fibrosing alveolitis, n = 3; pleural effusion,
n = 2; mesothelioma, bronchial carcinoma, and hemop-
tysis of unknown origin, each n = 1; no final diagnosis,
n = 3.
Central lung lavage fluid (CLF) (14) was collected from
4 male patients (1 nonsmoker, 3 current smokers; median
age 61 years, range 57-69 years); and the final diagnoses:
bronchial carcinoma, resolving pneumonia, hemoptysis
of unknown origin, and no final diagnosis, each n = 1.
An additional 22 patients (14 male; 8 nonsmokers, 4
exsmokers, and 10 current smokers; median age 56 years,
range 25-75 years) underwent bronchoscopy with bron-
choalveolar lavage (BAL) as a routine part of their diag-
nostic work-up. The final diagnoses on these patients
were: normal lung, n = 5; bronchial carcinoma, n = 5;
fibrosing alveolitis, n = 3; sarcoidosis, n = 3; pulmonary
effusion, n = 2; asperillosis, mesothelioma, bronchiec-
tasis, infection, no final diagnosis, each n = 1. One sub-
ject had mesothelioma with fibrosing alveolitis, and
therefore there are n = 23 diagnoses. The subjects found
to have normal lungs were investigated for unexplained
cough, hemoptysis, or cancerphobia.
No subject included in this study was undergoing treat-
ment with glucocorticoids at the time of bronchoscopy.
Coliection and Processing ofLavage Fluids
and Preparation for Western Blotting
PLF was collected as previously described (14). A 6F
double-lumened, balloon-tipped catheter was passed
through the biopsy channel ofan unwedged BF1T Olym-
pus bronchoscope and wedged by inflation of the balloon
at the level ofthe seventh or eighth generation. A 20-mL
portion of sterile, warmed 0.15 mole/L saline was instilled
through the second lumen and into the lung, below the
level ofthe wedged balloon. It was aspirated immediately
into a sterile trap, and the process was repeated until
100mL saline had been instilled into the lung and aspir-
ated into the same trap.
CLFwas collected as previously described (14). Briefly,
a 5F double-lumened, balloon-tipped catheterwas pass-
ed through the bronchoscope as previously described
and saline was instilled into the airways-this time above
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the level of the balloon, at the fifth or sixth generation.
Sterile, warmed 0.15 mole/L saline was instilled in 4 mL
portions and aspirated as previously described, until a
total of 20mL had been instilled into the airway and col-
lected into a sterile trap.
BAL was carried out as previously described (15).
Warmed, sterile 0.15 mole/L saline (50 mL) was instilled
through the biopsy channel ofthe bronchoscope that was
wedged at the third or fourth generation. The BAL fluid
(BALF) was withdrawn immediately into a sterile trap
and the process repeated a further three times.
All PLF, CLF, and 12 of the BALF were processed in
the same way. A sample of 1 to 2 mL was removed for
a total cell count using a Neubauer hemocytometer and
for a differential cell count following Wright-Geimsa
staining. The remaining fluid was filtered through wire
mesh and centrifuged at 300g at 40C for 15 min to pellet
the cells. (Cells from two BALF samples were used for
the culture studies described in the following section).
Lavage supernatants were stored in fractions at - 20°C
or lower until analysis.
Tbtal protein was measured by the method of Lowry
et al. (16) using bovine serum albumin as a standard.
Samples (2 mL) ofBALFand PLF were concentrated ap-
proximately 15-fold and 0.2 mL samples ofCLFwere con-
centrated approximately 10-fold by centrifugation in
Centricon units, with molecular weight cut-off 10 kDa,
for 3 hr at 3800g. The final protein concentration was
adjusted to 2.5 mg/mL with 0.15 mole/L saline. Samples
were boiled for 5 min with equal volumes ofsample buf-
fer, pH 8, containing Tris-HCl (10 mmole/L), EDTA (1
mmole/L), 5% (w/v) SDS, 10% (v/v) mercaptoethanoland
0.02% (w/v) bromophenol blue. The reduced samples
were stored at 200C prior to Western blotting.
Culture of BALF Cells and Incubation
of Cell Secretions with Recombinant
Human Lipocortin
The cells from 12 BALF samples were cultured as
follows: BALF cells and supernatants were separated as
previously described. The cells were washed in Hanks'
buffered salt solution (without Ca2+ or Mg2+), then
pelleted by repeat centrifugation at 300g for 15 min at
40C. The cells were then suspended in Dulbecco's modi-
fied Eagle's medium or low-protein hybridoma medium
and plated out at a concentration of 106/mL. After a 1-hr
adherence period, the conditioned media and floating
cells were removed and separated by centrifugation at
300g at 40C for 15 min. The media (CM 1) were stored
at - 200C. The adherent cells, mainly AM, were cultured
in fresh medium for a further 3 hr. Following that, the
conditioned media (CM 3) were removed, separated from
any residual nonadherent cells as previously described,
and stored as previously described.
Fractions of CM 1 and CM 3 were concentrated by
lyophilization or by centrifugation in Centricon units,
(cut-off, 10 kDa), at 3800g for 3 hr at 4°C. Pure recombi-
nant Lc 1 (80 Ag/mL) was incubated at 37°C with con-
centrated fractions ofCM 1 andCM 3 from the equivalent
of 2 to 20 x 106 elastase-secreting cells (PMN and
AM)/mL for periods of up to 48 hr. Fractions of the in-
cubation mixtures were removed at various time points,
and the reaction was terminated by boiling for 5 min with
an equal volume of sample buffer prepared as describ-
ed earlier. Because the amounts of CM varied between
patients, samples were not taken from every subject at
every time point. Collections were staggered so that suf-
ficient samples were available to carry out statistical
analysis on each time point. In order to determine
whether the BALF cells had released any Lc 1 into the
medium, samples of CM, to which no exogenous recom-
binant Lc 1 had been added, were prepared for Western
blotting as previously described. Prepared samples were
stored at - 200C until analysis.
Western Blotting for Lipocortin 1
SDS-polyacrylamide gel electrophoresis was perform-
ed on 8 to 25% gradient Phastgels using a PhastSystem
electrophoresis apparatus according to the manufactur-
er's instructions. A 1-uL fraction of lavage fluid, prepared
as previously described, was applied to each gel and
electrophoresed for approximately 30 min at 10 mAmps
per gel, maximum voltage, 100 V. Pure recombinant
human Lc 1 (80 Ig/mL) was prepared as described above
and used as a control on every gel. Molecular weight
markers (14.3-200 kDa) of variously dyed proteins were
used on each gel. Samples ofrecombinant Lc 1 (80 jAg/mL)
which had been incubated with CM, as previously
described, were electrophoresed in the same way.
Protein bands were transferred from gels to nitro-
cellulose paper by diffusion under pressure for 18 hr at
room temperature using Tris-glycine-methanol buffer,
pH 8 (Tris 6.25 mmole/L + glycine 250 mmole/L: metha-
nol, 4:1), as a carrier. Completion of protein transferwas
monitored by observing the colored bands of rainbow
markers.
The nitrocellulose sheets were agitated inTris-buffered
saline (TBS; 0.15 mole/L NaCl, 10 mmole/L Tris-HCl, pH
7), containing 3% (w/v) bovine serum albumin for 1 hr
at room temperature in order to block any remaining pro-
tein binding sites. The sheets were then shaken gently
for 24 hr at 40C (lavage supernatants), or 2 hr at room
temperature (CM/Lc 1 mixtures) with a specific rabbit
anti-recombinant human Lc 1 antibody diluted 1 in 1000
with washing buffer [WB; 10 mmole/L Tris-HCl, pH 7,
0.3 mole/L NaCl, 0.5% (v/v) Nonidet P-40] containing 3%
(w/v) bovine serum albumin. The remaining steps were
performed at room temperature. Nonspecifically bound
antibody was removed by exhaustive washing in WB
(without serum albumin). Following this, the blot was
exposed for 1 to 2 hr to goat anti-rabbit IgG, conjugated
to horseradish peroxidase diluted 1 in 1000 in WB, con-
taining 3% (w/v) bovine serum albumin. After further
washing in WB followed by TBS, the Lc 1 bands were
visualized by incubation of the blots in TBS containing
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diaminobenzidine, 125 ,ig/mL and H202, 0.04 1L/mL.
After a 30- to 60-min incubation, the reaction was ter-
minated by washing the blot in TBS.
Any lavage supernatants that were negative for Lc 1
on Western blotting were immunoblotted using larger
amounts of sample. Briefly, 50-IAL portions of concen-
trated, reduced lavage fluid were applied directly to
nitrocellulose paper using a dot-blotting apparatus ac-
cording to the manufacturer's instructions. Any Lc 1 in
the sample was then visualized using the antisera and
detection system described previously.
Identification of the Partially Degraded
Lc 1 Band
Duplicate samples of pure recombinant Lc 1 and Lc
1 partially degraded by incubation with a sample ofCM
1 were electrophoresed as previously described on a
single gel. The gel was then bisected and one set of
samples Western blotted as described above. The second
set of samples was blotted using a first antibody raised
to a peptide with an identical amino-acid sequence to
residues 13 to 26 of human Lc 1. This region of the N-
terminal portion of Lc 1 contains the tyrosine phos-
phorylation site situated at position 21 (5).
The antibody was diluted 1 in 100 with WB contain-
ing3% (w/v) bovine serum albumin and was left bathing
the nitrocellulose sheet for 24 hr. The rest of the blot-
ting procedure was as previously described, except that
the horseradish peroxidase-conjugated second anti-
body was diluted 1 in 500, not 1 in 1000, and was left
in contact with the blot for 3 hr.
Blot Scanning: Use and Validation
The Lc bands detected on each individual track of
every blot were scanned using a Chromoscan 3 gel scan-
ner. Each scan was 0.3mm wide. A scan length of 5 mm
was long enough to include the bands of native and
degraded Lc 1. The scannerwas set in reflectance mode
to measure optical density at 530 nm. The machine defm-
ed the limits of each band according to preprogrammed
parameters, and it calculated the total and relative den-
sities of all the bands within a 5mm scan. It could there-
fore calculate the percentage of the total Lc 1 detected
in the parent (37 kDa) and proteolyzed (34 kDa) forms.
The between-blot reproducibilities of the absolute and
relative densities of the 37 and 34 kDa Lc 1 bands were
determined by pooling the control data from every
Western blot and calculating the coefficient of variance
ofthese parameters. Western blots with identical samples
of pure Lc 1 on every track or with a different amount
of pure Lc 1 (0-500 ng) on every track were analyzed
in the same way to determine within-blot reproducibili-
ty and to determine whether optical density was linear
with respect to the amount of Lc 1 applied to the gel.
Effect of Human Neutrophil Elastase on
Recombinant Human Lc 1
Human neutrophil elastase (NE)was active site titrated
using constants taken from Nakajima et al. (1?). Recom-
binant human Lc 1 was incubated with active (NE) at
37°C in low protein hybridoma medium in molar ratios
of 0.01 to 1 (NE) to 1 (Lc 1). Fractions of incubation mix-
tures were removed at intervals up to 48 hr. The reac-
tion was terminated and the samples analyzed by
Western blotting as previously described.
Determination of Elastase Activity (EA)
Elastase activities (EA) of samples of CM and BALF,
and PLF supernatants were measured against insoluble
elastin (from bovine ligamentum nuchae) tritiated as
previously described (18). EA was assayed by the method
of Banda and Werb (18), modified as previously describ-
ed (15). HumanNE active site, titrated as earlier describ-
ed, was used as a standard.
Statistics
The Mann-Whitney U test was used to compare lavage
data, while the Wilcoxon signed rank test for paired data
was used to analyze the effect ofCM on Lc 1. The Spear-
man rank correlation coefficient, corrected for tied
values, was calculated to assess the relationship between
variables. In all analyses, p < 0.05 in a two-tailed test
was taken as statistically significant.
Results
Validation of Scanning Technique
There are two ways of analyzing the degradation of
native Lc 1 (i.e., from 37 to 34 kDa) from a Western blot
scan. The first involves measuring the reduction in op-
tical density of the 37 kDa band. This method requires
a linear relationship between optical density and the
amount of protein in the band. However, the relation-
ship was nonlinear, particularly at high concentrations
ofLc 1. Furthermore, when equal amounts ofexogenous
Lc 1 were analyzed on each track, the reproducibility
of total optical density measurements was very poor
(lible 1). The alternative method ofestimating degrada-
tion is to measure the total density ofthe 37 kDa (parent)
band plus that ofthe 34 kDa (degraded) band and calcu-
late the proportion of the total density contributed by
each band. Using this method, it was found that the con-
tribution of the 37 kDa band to the total optical density
was very consistent within and between blots (Thble 1)
and irrespective of the total amount of Lc 1 applied to
the gel. Therefore, this measurement has been used
throughout the study.
Comparative Analysis of BALF, PLF,
and CLF
Lipocortin. LC 1 was detected by Western blotting
in PLF from all healthy volunteers and in 8 ofthe 11 PLF
samples from patients. In addition, Lc 1 was detected
in 11 of the 12 BALF samples tested, but it was not
detected in CLF from any subject. However, when
samples of negatively staining lavage fluids were dot-
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lkble 1. Validation of scanning technique.
Coefficient
of
Parameter Condition n x + SDa variance
Total densityb Within blot 7 3144 + 1006 32%
Total density Between blot 45 2240 + 1822 81%
37 kDa, Within blot 14 91 + 3 2%
% of total
37 kDa, Between blot 22 93 ± 5 5%
% of total
aSD, standard deviation.
bTotal density is measured in arbitrary units.
blotted, Lc 1 was then detected in all CLF and PLF and
in all but one of the BALF (data not shown).
The proportions of native (37 kDa) to degraded
(34 kDa) Lc 1 varied considerably between subjects.
However, PLF from volunteers contained at least 70% Lc
1 in the native form (Fig. 1), which was significantly
higher than in PLF from patients (lible 2). In contrast,
in BALF, the proportion of 37 to 34 kDa Lc 1 was more
variable and there was no statistically significant dif-
ference in the percentage of Lc 1 in the native form bet-
ween BALF from patients with normal and abnormal
lungs (Thble 2).
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FIGURE 1: Percentage of 37 kDa Lc 1 present in PLF and BALF from
subjects with normal and abnormal lungs. See text and 'lible 2 for
statistically significant differences between groups and for correla-
tions with other lavage parameters.
Table 2. Recovery of fluid and cells, protein levels, elastase activities and proportions of native Lc 1 in different types
of lavage fluid from subjects with normal and abnormal lungs.
Percent of fluid Cell profile, Tbtal protein, 37 kDa Lc 1,
Group n recovered Cells, x 106 % total mg EA, ng/mg protein % totala
Normal/volunteer PLF 6 33(21-40) 16.3(12.2-21.3) AM 94(81-100) 7.33(5.25-17.55) 27(3-103) 95(73-98)
PMN 4(0-14)
LYM 4(0-7)
Abnormal PLF 11 31(10-68) 4.7(0.1-9.6)b AM 87(58-99) 1.88(0.39-14.15)b 36(0-559) 53(0-100)"
PMN 2(1-25)
LYM 8(0-24)
Normal patient BALF 5 67(31-75)c 27.5(5.4-108.8) AM 91(80-96) 15.88(5.59-47.85) 175(72-395)C 63(0-97)b
PMM 1(0-5)
LYM 4(3-20)
Abnormal BALF 7 39(18-58) 15.3(4.1-580)d AM 55(45-79)e 18.50(7.56-41.70)d 255(38-2860) 32(8-73)
PMN 35(7-56)f
LYM 11(1-15)
Abnormal CLF 4 33(15-45) 0(0-0)g AM ND 0.39(0.02-0.73)g NA ND
PMN ND
LYM ND
a Only samples positive for Lc 1 on Western blotting are included; see Figure 1.
b < Normal PLF.
c > Normal PLF.
d > Abnormal PLF.
e < Abnormal PLF and normal BALF.
f > Abnormal PLF and normal BALF.
g < Abnormal PLF and abnormal BALF.
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When PLF and BALF were compared to each other,
it was found that PLF from volunteers had a significantly
greater percentage of Lc 1 in its native form than BALF
from patients with normal lungs (Table 2).
Other Variables. Although there was no statis-
tically significant difference in the percentage of in-
stilled fluid recovered in PLF from volunteers compared
to that from patients, more protein was recovered from
volunteer's PLF (lible 2). More cells were recovered from
volunteer's PLF, but the cell profiles were not significant-
ly different to those from patients. EA/mg protein did
not differ between the groups and neither did EA/lavage
(data not shown), despite the significant difference in
protein recoveries.
There were no significant differences in fluid recover-
ies, levels of total protein, or numbers of BALF cells in
BALF from patients with normal lungs compared to
those with abnormal lungs (Thble 2). However, a signifi-
cantly greater proportion of the recovered cells in ab-
normal BALF were PMN (lible 2). EA/mg protein did
not differ between the two sets of BALF.
When BALF and PLF from subjects with healthy lungs
were compared, a greater percentage of the instilled
fluid was recovered after BALF, but the total protein,
number, and type of cells recovered was not significant-
ly different between the lavage types. However, the
EA/mg protein was significantly greater in BALF than
in PLF (Thble 2).
Comparison of BALF and PLF from subjects with ab-
normal lungs showed no difference in the percentage of
instilled fluid recovered. However, protein levels were
higher in BALF than in PLF. Significantly more cells were
recovered in BALF from patients with abnormal lungs,
and the proportion of PMN was greater than in abnor-
mal PLF (Thble 2). EA/mg protein tended to be greater
in abnormal BALF than in PLF from patients with ab-
normal lungs, but this difference was not statistically
significant.
The percentage of instilled fluid recovered after CLF
was not significantly different to that after other types
of lavage. Cells were not detected in any of the CLF, and
protein levels were significantly lower than in other
lavage types (Table 2). EA was not assayed in these
samples, because of the small volumes of material
available.
Correlations ofLipocortin with Other Variables.
No statistically significant correlations were found
between the proportion of Lc 1 in the 37-kDa form and
any variable in PLF from patients or volunteers.
However, in BALF from patients with abnormal lungs,
there was an inverse correlation between the proportion
of LC 1 remaining in the native (37 kDa) form and the
number of PMN in the lavage (n = 7 pairs, rs = - 0.8214,
p < 0.05). In addition, there was a tendency towards an
inverse correlation between the percentage of native (37
kDa) Lc 1 and EA/mg protein (n = 7 pairs, rs = - 0.7500,
p < 0.10) in BALF from patients with abnormal lungs.
No such relationships were observed in BALF from pa-
tients with apparently normal lungs.
Analysis of BALF Cell Secretions in
CM 1 and CM 3 and Their Effect on
Recombinant Lc 1
Under the conditions employed in this study, Lc 1
could not be detected in any sample of CM before the
addition of exogenous recombinant protein.
The cellular equivalents of the CM 1 and CM 3 in-
cubated with recombinant Lc 1 are shown in TAble 3.
PMN were present in CM 1, but not CM 3. EA/105 elas-
tase secreting cells (ESC) was higher in CM 1 than in CM
3 (CM 1, 3.3 [0.5-10.0 ng/105 cells]; CM 3, 0.5 [0-9.7
ng/105 cells] median [range] CM 3 < CM 1, p < 0.05).
Therefore, because for any given subject, Lc 1 was in-
cubated with CM 1 and CM 3 derived from equivalent
numbers of elastase secreting cells, the EA/Lc 1 ratio was
significantly higher when Lc 1 was incubated with CM
1 than CM 3 (lible 3). There were no significant correla-
tions between EA and PMN or AM number in CM 1 or
CM 3.
All but two of the CM 1 tested were able to degrade
recombinant Lc 1 (Thble 4), although some samples were
much more active in this respect than others. CM 3 were
generally less active than CM 1 (Fig. 2), although the
groups were not statistically significantly different to
each other, because of the variability between different
CM 1 samples in the capacity to degrade Lc 1.
InCM 1 the disappearance ofparent (37 kDa) Lc 1 was
positively correlated to the PMN/Lc 1 ratio in the samples
after 1 and 6 hr incubations, and it tended to be
correlated after 24 hr (Tible 4; 1 hr, n = 10 pairs,
rs = -0.7200,p< 0.05; 6hr, n = 6pairs, rs = -0.9241,
p < 0.05; 24 hr, n = 10 pairs, rs = -0.6398, p < 0.10).
In contrast, the number ofAM was inversely correlated
with the disappearance of37-kDa fonn of Lc 1 at the 6-hr
time point (RTble 4; n = 6 pairs, rs = -0.6891,p < 0.05).
The disappearance of parent Lc 1 was not significantly
correlated to EA/Lc 1 ratio in CM 1 at any time point.
There were no statistically significantly correlations be-
tween the percentage of native Lc 1 remaining and any
of the parameters measured in CM 3.
Identification of the Partially Degraded
Form of Lc 1
Although the antibody raised to an amino-acid se-
quence in the N-terminal portion of native Lc 1 cross-
reacted with the 37-kDa protein, it failed to cross-react
with the 34 kDa form produced following incubation for
3 hr with CM 1 from a mixed population of cells (Fig. 3).
Effect of Pure Human NE on Recombinant
Lc 1
Incubation ofpureNE and Lc 1 at a molar ratio of 0.1:1
or 0.5:1 resulted in complete degradation of the 37-kDa
protein to the 34-kDa form within 0.5 hr, while at a ratio
of 1:1, no lipocortin-derived protein of any molecular
weight could be detected on a Western blot following a
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Ibble 3. Cell profile from whichCM 1 andCM 3 were derivedand
the effect of these cells on pure recombinant Lc 1.
Ratio/Lc 1 Ratio/Lc 1 Control
CM 1 CM 3 medium
Parameter n > 10 n > 9 n = 2
ESC, x 105a 1.0(0.4-2.0) 1.0(0.4-1.0) 0
AM, x 105 0.7(0.3-10O)b 1.0(0.4-1.0)c 0
PMN, x 105 O. 1(0-0.5)d O(0_0)e 0
EA, NEE ngf 3.0(0.5-9.1) 0.3(0-9.7)e 0
Table 4. Time course of Lc 1 degradation by CM 1 and CM 3.
37 kDa, 37 kDa,
% remaining % remaining Control
Time of CM 1 CM 3 medium
incubation, hr n > 6 n = 6 n = 3
0 100 100 100
0.5 94(29-108)g - 102
1.0 91(0-l0l)g 101(55-1 10) 100
3.0 81(0-102)8 100(0-114) 99
6.0 42(0-97)g 101(0-105) 102
18.0 4(0-105)g 101(0-114) -
24.0 32(0-105)g 97(0-99)g 101
48.0 0(0-105)g 86(0-101) 100
aElastase secreting cells.
b + ve correlation with 37 kDa remaining in CM 1, 6 hr.
C> CM 1.
d
-ve correlation with percentage of percentage of 37 kDa
remaining in CM 1, 1 hr and 6 hr.
e< CM 1.
fneutrophil elastase equivalents.
9< time 0 hr.
See text for rs values. p < 0.05 for all data.
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FIGURE 2: Median percentage of 37 kDa human recombinant Lc 1 re-
maining after different times of incubation with samples of con-
ditioned media (CM 1 and CM 3). CM 1: Percentage of 37 kDa re-
maining < time 0 hr at all incubations times of 1 hr or more, p <
0.05. CM 3: Percentage of 37 kDa remaining < time 0 hr only after
24 hr incubation, p < 0.05.
FIGURE 3: Comparison of Western blots of pure recombinant human
Lc 1 usingantibodies raised to the whole Lc 1 molecule (tracks A-D)
or to a peptide consisting of residues 13 to 26 from the N-terminal
portion of the molecule (tracks E-G). Track D contains molecular
weight markers. The upper horizontal line corresponds to a
molecular weight of 37 kDa, the lower to a weight of 34 kDa. Tracks
C and G contain untreated pure recombinant human Lc 1. A small
proportion is in the 34-kDa form, but only the parent protein is
detected by antibodies to the N-terminal sequence. Tracks A, B,
E, and Fcontain recombinant human Lc 1 pretreated for 3 hr with
a sample of CM 1. Tracks A and B show that the majority of the
Lc 1 has a molecular weight of 34 kDa. No bands are visible on tracks
E and F, demonstrating that the 34 kDa portion of the molecule
lacks the N-terminal sequence.
0.5 hr incubation (Fig. 4). Decreasing the NE:Lc 1 ratio
to 0.01:1 reduced the rate of loss of lipocortin-derived
protein. However, even at this low ratio, all the protein
was in the 34-kDa form by 0.5 hr. After a 24-hr incuba-
tion with NE at a ratio of 0.01:1 (NE:Lc 1), no lipocortin-
derived protein was detectable on a Western blot (Fig. 4).
Discussion
Lipocortin 1 was detected in all but one of the lavage
samples analyzed, irrespective of the clinical status or
smoking history of the subjects. We believe this to be the
first report of the presence of any member ofthe lipocor-
tin family in human lung lavage fluid. In addition, it has
been shown that, although in healthy volunteers the Lc
1 was predominantly in its native form, in many of the
lavage samples from patients, a high proportion of the
protein was partially degraded. Our in vitro studies sug-
gest that this degradation could be caused by one or more
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FIGURE 4. Western blot of recombinant human Lc 1 following prein-
cubation with NE at different molar ratios. (A) Track G contains
molecular weight markers. Tracks A-D contain Lc 1 pretreated with
NE at a ratio of 0.5:1 (NE:Lc 1) for 1, 10, 30, and 60 min respective-
ly. After a 1-min exposure, the majority of the Lc 1 is partially
degraded. By 10 min it is all partially degraded, and by 60 min it
is completely proteolyzed. Tracks E and F contain Lc 1 pretreated
with NE at a ratio of 1:1 for 10 and 30 min, respectively. Following
a 10-min exposure, all the Lc 1 is partially degraded, while by 30
min it is completely proteolyzed. (C). Track H contains molecular
weight markers. Tracks A-G contain recombinant human Lc 1
pretreated with NE at a molar ratio of 0.01:1 (NE:Lc 1) for 0, 0.5,
1, 3, 6, 24, and 48 hr, respectively. Within 30 min all the Lc 1 has
been proteolyzed to the 34 kDa.
products of the PMN, while studies with a specific anti-
body indicate that this partially degraded Lc 1 lacks the
N-terminal portion that we believe to be essential for full
anti-inflammatory function in vivo and in cellular
systems in vitro (Flower et al., unpublished observation).
In previous studies, lipocortins have been detected in
lung tissue from the rat (6), from cattle (7) and in feline
tracheal rings (19). The most likely source of the Lc 1
detected in our lung lavage fluids is the AM, since studies
in the rat (5,20) and on cell lines from various species
(6) show that monocytes and macrophages are frequent-
ly rich sources of lipocortins. Lipocortins require Ca2 +
to remain attached to the plasma membrane, and thus,
lavage of the lung with a calcium-free solution (NaCI)
may result in some of the Lc 1 becoming detached from
theAM surface and solubilized in the supernatant frac-
tion of the lavage fluid. However, the possibility that
Lc 1 exists in a free form at the epithelial surface can-
not be excluded.
In the current study, amounts of Lc 1 could not be
quantified. This is probably because factors such as am-
bient temperature and the activity of conjugated
horseradish peroxidase are difficult to control but may
modify the density of staining. In contrast, the relative
proportion of 37 kDa to proteolyzed (34 kDa) Lc 1 was
very reproducible (lible 1) and has, therefore, been
determined.
Taking into account the degree of resolution obtained
with SDS-polyacrylamide electrophoresis, it is probable
that the 34-kDa band observed throughout the current
study is the same or very similar to the 33-kDa species
generated from human recombinant Lc 1 by Huang et
al. (9). These authors showed their fragment to be clip-
ped 30 residues from the N-terminal ofthe precursor (37
kDa) molecule. In addition, an earlier study by the same
group (6) demonstrated that some of the endogenous
Lc 1 isolated from rat peritoneal extracts was clipped in
the same region. Thus, it seems that both in vivo and
in vitro, this region of Lc 1 is the most vulnerable to pro-
teolysis. In the current study, it has been shown that the
partially degraded Lc 1 occurs in the human lung ('lble
1) and that NE and possibly other products of the PMN
are capable of causing such degradation (Thble 3). In ad-
dition, this study has shown that the 34-kDa form lacks
the N-terminal end of the parent protein since it does
not cross-react with an antibody to this epitope of the
molecule (Fig. 3), increasing the probability that we have
studied the same molecular species as Huang et al. (9).
Although the results of cell-free PLA2 assays (9) suggest
that the clipped form inhibits PLA2, other authors con-
sider cell-free systems to be flawed (21). Therefore,
because we believe bioassay to be more relevant to the
situation in man, we are confident that measurement
of the ratio of 37:34-kDa forms is actually a measure of
the ratio of functional:nonfunctional Lc 1.
The results of the in vitro studies (Thble 3) show that
the recombinant Lc 1 was much more actively degrad-
ed by conditioned media from mixed populations of cells
containing AM and PMN than that from adherent AM
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alone, suggesting that the degraded Lc 1 observed in lung
lavage samples may be the result of PMN activity. This
was supported by the observation that degradation of
37 kDa Lc 1 was related to the number of PMN in CM
1 (Thble 3). It is not clear from these data what factor
(or factors) released into CM1 by the PMN is responsible
for the breakdown of Lc 1. Even though pure NE is able
to proteolyze Lc 1 (Fig. 3), no relationship was observed
between EA and proteolysis of Lc 1 in our in vitro ex-
periment. There are a number of possible reasons for
this; EA is a measure of activity from all elastolytic en-
zymes, some of which may not degrade Lc 1, thus in the
in vitro study, metalloelastase from the AM (22) may
have made a significant contribution to the EA
measured. Furthermore, it is possible that two or more
enzymes act in sequence to degrade Lc 1-for example,
studies with the pure protein show thatNE first degrades
Lc 1 to the 34-kDa form (Fig. 4). This may cause a three-
dimensional change to the lipocortin structure that
makes it more susceptible to attack by other PMN pro-
teases, for example, cathepsins. Equally, an unidentified
protease could make the initial clip in the parent Lc 1
and NE could perform subsequent degradation.
In view of the animal studies showing macrophages
to be rich in lipocortins (5,20), it is perhaps surprising
that endogenous Lc 1 was not detected in media where
AM had been cultured (CM). However, the CM samples
were taken from very small numbers of cells and had
media from a larger cell population been investigated or
the sensitivity of the detection system been increased,
Lc 1 might have been detected. Alternatively, because
the tissue culture media contain Ca2 +, any Lc 1 pro-
duced by the AM may have remained attached to the
plasma membrane and, thus, would not be detected in
CM. Alternatively, Lc 1 released into the CM may have
already been proteolyzed to small peptides that would
not be detected on a Western blot. A final possibility is
that human AM synthesize a member of the lipocortin
family other than Lc 1, which would not cross-react with
our antibody. Further studies will be necessary to dif-
ferentiate between these possibilities.
The results of the immunoblotting experiments in-
dicate that some samples of lavage fluid contain more
Lc 1 than others. While the reasons for differences be-
tween subjects undergoing the same type of lavage are
unclear, the low LC 1 levels in CLF, compared toPLF and
BALF, may reflect the paucity ofAM in the large airways
washed during the central lavage procedure. However,
it is also possible that in some lavages, particularly in CLF,
which contain relatively high protease activities (14), the
Lc 1 was degraded to small peptides that would not be
detected on a Western blot.
The lavage data (Tble 2) suggest that the proportion
of native to partially degraded Lc 1 reflects both the
health of the subject and the region of the lung sam-
pled. PLF contains proportionally less 34 kDa Lcl than
BALF. Unlike BALF, PLF contains no material from above
the seventh generation, so it is likely that much of the
34 kDa Lc 1 in BALF is from the airways. Analysis ofmore
concentrated samples of CLF or immunoblotting with
the antibody to the N-terminal epitope would clarify this
point. It is possible that the mucociliary escalator is a
route for clearance, either of nonfunctional lipocortin
or of cells (probably AM) carrying nonfunctional lipocor-
tin. Alternatively, more degradation of lipocortin may
occur in the upper respiratory tract than in the
periphery, a possibility supported by earlier studies from
this laboratory showing that protease activity per unit
albumin and the number ofPMN (expressed as a percent-
age of the total cell population) are both higher in CLF
than in PLF (14). Also, it is known that phosphorylation
of the tyrosine residue at position 21 of Lc 1 down-
regulates its PLA2-inhibitory capacity (23) and that once
phosphorylated, it is more susceptible to degradation.
Thus, it is possible that in the upper respiratory tract,
cells are stimulated (for example, to phagocytize and
degrade large inhaled particles deposited in the upper
airways), and that the subsequent downregulation of
lipocortin by phosphorylation results in an increase in
proteolysis of Lc 1.
Summary
In summary, we have demonstrated that Lc 1 is present
at the epithelial surface of the human lung, usually in
a variable mixture of native and partially degraded
forms. This study suggests a role for the PMN in inactiva-
tion of this protein that may be important in inflam-
matory lung diseases. Further studies to bioassay and
quantify the Lc 1 will be necessary before the physio-
logical significance of these observations can be fully
evaluated.
An influx of PMN during inflammation may be a
mechanism ofdownregulating lipocortins and would per-
mit the inflammatory response necessary to destroy a
provocative stimulus. Removal of the stimulus with
reduced PMN numbers would halt lipocortin degrada-
tion. Equally, it is possible that in chronic inflammation,
the inactivation of lipocortin is pathological, perhaps
when the stimulus cannot be destroyed, for example, in
asbestosis or pneumoconiosis. In such situations a
massive increase in lipocortin synthesis, induced by high
doses of exogenous glucocorticoids, may then be the only
way of halting the inflammatory process.
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